Cargando…
Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset
Autores principales: | Russo, Roberto, Gasparini, Giulia, Cozzani, Emanuele, D’Agostino, Federica, Parodi, Aurora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895245/ https://www.ncbi.nlm.nih.gov/pubmed/35251024 http://dx.doi.org/10.3389/fimmu.2022.834316 |
Ejemplares similares
-
May bullous pemphigoid be worsened by COVID-19 vaccine?
por: Cozzani, Emanuele, et al.
Publicado: (2022) -
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
por: Russo, Roberto, et al.
Publicado: (2020) -
Considerations on SARS-CoV-2 vaccines in patients with autoimmune blistering diseases
por: Cozzani, Emanuele, et al.
Publicado: (2021) -
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
por: Russo, Roberto, et al.
Publicado: (2022) -
Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report
por: Herzum, Astrid, et al.
Publicado: (2022)